Drug Type Fusion protein |
Synonyms F16 IL2 fusion protein, Teleukin |
Target |
Mechanism IL-2R agonists(Interleukin-2 receptor agonists), tenascin inhibitors(Tenascin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | CH | 09 Mar 2017 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | DK | 25 Oct 2013 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | AT | 25 Oct 2013 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | GB | 25 Oct 2013 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | DE | 25 Oct 2013 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | ES | 25 Oct 2013 | |
Metastatic Merkel Cell Carcinoma | Phase 2 | FR | 25 Oct 2013 | |
Relapsing acute myeloid leukemia | Preclinical | DE | 02 Dec 2016 |